Document is current
Any future updates will be listed below
-
Authors
Brownstien, Michal
Lazar, Michal
Botvinnik, Alexander
Shevakh, Chloe
Blakolmer, Karin
Lerer, Leonard https://orcid.org/0000-0001-9189-4991
Lifschytz, Tzuri
Lerer, Bernard https://orcid.org/0000-0002-9914-632X
-
Funding
Funding for this research was provided by:
Parow Emtheobiosciences (ParowBio) Back of the yards algae sciences
- License Information
-
More Information
Article History
Received: 25 June 2024
Revised: 2 October 2024
Accepted: 7 October 2024
First Online: 11 October 2024
Competing interests
: LL is the Founder and CEO of Back of the Yards Algae Sciences (BYAS) and a Founder of Parow Entheobiosciences (ParowBio). KB is a Founder and CEO of Parow Entheobiosciences (ParowBio). BL is a consultant to Back of the Yards Algae Sciences (BYAS) and Parow Entheobiosciences (ParowBio). LL, BL, and KB submitted an international patent application (No. WO 2023/164092 A1 “Treatment of Psychiatric Disorders, Brain Injuries, and Autism Spectrum Disorder”) which was published on 31 August 2023 that includes the possibility of treating OCD with psychedelic mushroom extract. Patent assigned to Parow Entheobiosciences.
